New immunotherapy combo shows promise in advanced cancers
NCT ID NCT03860272
First seen Apr 25, 2026 · Last updated May 08, 2026 · Updated 3 times
Summary
This early-phase study tests two experimental immunotherapy drugs (botensilimab and balstilimab) in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the best dose. About 499 participants with various cancers, including lung, ovarian, and colorectal cancer, are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
HonorHealth Research Institute
Scottsdale, Arizona, 85258, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Providence Portland Cancer Center
Portland, Oregon, 97213, United States
-
Royal Marsden Hospital NHS Foundation Trust
London, SW3 6JJ, United Kingdom
-
Saint John's Cancer Institute
Santa Monica, California, 90404, United States
-
The Angeles Clinic & Research Institute, a Cedars-Sinai Affiliate
Los Angeles, California, 90025, United States
-
The University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78229, United States
-
UCLA Santa Monica Hematology Oncology
Los Angeles, California, 90095, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
-
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
-
University of Southern California Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
Yale Cancer Center
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.